Genetically humanized mouse models of drug metabolizing enzymes and transporters and their applications

Xenobiotica

Volumn 44, Issue 2, 2014, Pages 96-108

  Scheer, Nico ^a   Wolf, C Roland ^b  

^a TaconicArtemis   (Germany)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Bioavailability; Clearance; Drug metabolising enzymes; Drug drug interactions; Human metabolites; Transporters

Indexed keywords

BUFURALOL; CYTOCHROME P450; DEBRISOQUINE; DOCETAXEL; DRUG METABOLITE; DRUG METABOLIZING ENZYME; KETOCONAZOLE; LOPINAVIR; METHOTREXATE; MIDAZOLAM; PACLITAXEL; QUINIDINE; RITONAVIR; TRIAZOLAM; XENOBIOTIC AGENT;

DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXPOSURE; DRUG INTERACTION; GENE EXPRESSION; HUMAN; MOUSE MODEL; NONHUMAN; PERINATAL DEVELOPMENT; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; TISSUE DISTRIBUTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYMES; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, ANIMAL; PHARMACOLOGICAL PROCESSES; RISK ASSESSMENT;

EID: 84893103243     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.815831     Document Type: Review

References (76)

1. Butura A, Nilsson K, Morgan K, et al. (2009). The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model. J Hepatol 50:572-83.
2. Cai H, Nguyen N, Peterkin V, et al. (2010). A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos 38: 879-86.
3. Cao W, Chau B, Hunter R, et al. (2005). Only low levels of exogenous N-acetyltransferase can be achieved in transgenic mice. Pharmacogenomics J 5:255-61.
4. Cao W, Strnatka D, McQueen CA, et al. (2010). N-acetyltransferase 2 activity and folate levels. Life Sci 86:103-6.
5. Chen C, Meng L, Ma X, et al. (2006). Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 318:1330-42.
6. Chen S, Beaton D, Nguyen N, et al. (2005). Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280:37547-57.
7. Cheng J, Ma X, Krausz KW, et al. (2009). Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminopheninduced toxicity. Drug Metab Dispos 37:1611-21.
8. Cheung C, Akiyama TE, Ward JM, et al. (2004). Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha. Cancer Res 64:3849-54.
9. Cheung C, Loy S, Li GX, et al. (2011). Rapid induction of colon carcinogenesis in CYP1A-humanized mice by 2-amino-1-methyl- 6-phenylimidazo[4,5- b]pyridine and dextran sodium sulfate. Carcinogenesis 32:233-9.
10. Cheung C, Ma X, Krausz KW, et al. (2005a). Differential metabolism of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice humanized for CYP1A1 and CYP1A2. Chem Res Toxicol 18: 1471-8.
11. Cheung C, Yu AM, Chen CS, et al. (2006). Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther 316:1328-34.
12. Cheung C, Yu AM, Ward JM, et al. (2005b). The cyp2e1-humanized transgenic mouse: role of cyp2e1 in acetaminophen hepatotoxicity. Drug Metab Dispos 33:449-57.
13. Corchero J, Granvil CP, Akiyama TE, et al. (2001). The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse. Mol Pharmacol 60:1260-7.
14. Derkenne S, Curran CP, Shertzer HG, et al. (2005). Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1-1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice. Pharmacogenet Genomics 15:503-11.
15. Devoy A, Bunton-Stasyshyn RK, Tybulewicz VL, et al. (2012). Genomically humanized mice: technologies and promises. Nat Rev Genet 13:14-20.
16. Dragin N, Dalton TP, Miller ML, et al. (2006). For dioxin-induced birth defects, mouse or human CYP1A2 in maternal liver protects whereas mouse CYP1A1 and CYP1B1 are inconsequential. J Biol Chem 281: 18591-600.
17. Dragin N, Uno S, Wang B, et al. (2007). Generation of 'humanized' hCYP1A1-1A2-Cyp1a1/1a2(-/-) mouse line. Biochem Biophys Res Commun 359:635-42.
18. Felmlee MA, Lon HK, Gonzalez FJ, Yu AM. (2008). Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Drug Metab Dispos 36:435-41.
19. Frederick CB, Obach RS. (2010). Metabolites in safety testing: "MIST" for the clinical pharmacologist. Clin Pharmacol Ther 87: 345-50.
20. Fujiwara R, Nguyen N, Chen S, Tukey RH. (2010). Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc Natl Acad Sci U S A 107:5024-9.
21. Giacomini KM, Huang SM, Tweedie DJ, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215-36.
22. Granvil CP, Yu AM, Elizondo G, et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31:548-58.
23. Guengerich FP. (2008). Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70-83.
24. Guo GL, Moffit JS, Nicol CJ, et al. (2004). Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol Sci 82: 374-80.
25. Harden CL. (2002). Pregnancy effects on lamotrigine levels. Epilepsy Curr 2:183.
26. Hasegawa M, Kapelyukh Y, Tahara H, et al. (2011). Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 80:518-28.
27. Holmstock N, Gonzalez FJ, Baes M, et al. (2013). PXR/CYP3A4- humanized mice for studying drug-drug interactions involving intestinal P-glycoprotein. Mol Pharm 10:1056-62.
28. Jiang Z, Dalton TP, Jin L, et al. (2005). Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1-CYP1A2 locus. Hum Mutat 25:196-206.
29. Kathirvel E, Chen P, Morgan K, et al. (2010). Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver. J Gastroenterol Hepatol 25: 1136-43.
30. Kathirvel E, Morgan K, French SW, Morgan TR. (2009). Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 21:973-83.
31. Kazuki Y, Kobayashi K, Aueviriyavit S, et al. (2012). Transchromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Hum Mol Genet 22:578-92.
32. Lee SS, Buters JT, Pineau T, et al. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063-7.
33. Leff MA, Epstein PN, Doll MA, et al. (1999). Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J Pharmacol Exp Ther 290:182-7.
34. Li F, Patterson AD, Krausz KW, et al. (2012). Metabolomics reveals the metabolic map of procainamide in humans and mice. Biochem Pharmacol 83:1435-44.
35. Li Y, Yokoi T, Kitamura R, et al. (1996). Establishment of transgenic mice carrying human fetus-specific CYP3A7. Arch Biochem Biophys 329:235-40.
36. Lofgren S, Baldwin RM, Carleros M, et al. (2009). Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos 37: 1505-12.
37. Lofgren S, Baldwin RM, Hiratsuka M, et al. (2008). Generation of mice transgenic for human CYP2C18 and CYP2C19: characterization of the sexually dimorphic gene and enzyme expression. Drug Metab Dispos 36:955-62.
38. Lu Y, Wu D, Wang X, et al. (2010). Chronic alcohol-induced liver injury and oxidant stress are decreased in cytochrome P4502E1 knockout mice and restored in humanized cytochrome P4502E1 knock-in mice. Free Radic Biol Med 49:1406-16.
39. Ma X, Cheung C, Krausz KW, et al. (2008). A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4. Drug Metab Dispos 36:2506-12.
40. Maglich JM, Stoltz CM, Goodwin B, et al. (2002). Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-46.
41. Miners JO, Robson RA, Birkett DJ. (1986). Paracetamol metabolism in pregnancy. Br J Clin Pharmacol 22:359-62.
42. Morgan K, French SW, Morgan TR. (2002). Production of a cytochrome P450 2E1 transgenic mouse and initial evaluation of alcoholic liver damage. Hepatology 36:122-34.
43. Morimura K, Cheung C, Ward JM, et al. (2006). Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27:1074-80.
44. Nebeker JR, Barach P, Samore MH. (2004). Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 140:795-801.
45. Omiecinski CJ, Vanden Heuvel JP, Perdew GH, Peters JM. (2011). Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. Toxicol Sci 120:S49-75.
46. Paine MF, Hart HL, Ludington SS, et al. (2006). The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-6.
47. Powley MW, Frederick CB, Sistare FD, DeGeorge JJ. (2009). Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s. Chem Res Toxicol 22:257-62.
48. Robison TW, Jacobs A. (2009). Metabolites in safety testing. Bioanalysis 1:1193-200.
49. Ross J, Plummer SM, Rode A, et al. (2010). Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine non-genotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol Sci 116:452-66.
50. Sarikaya D, Bilgen C, Kamataki T, Topcu Z. (2006). Comparative cytochrome P450 -1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level. Biopharm Drug Dispos 27:353-9.
51. Scheer N, Balimane P, Hayward MD, et al. (2012a). Generation and characterization of a novel multidrug resistance protein 2 humanized mouse line. Drug Metab Dispos 40:2212-18.
52. Scheer N, Kapelyukh Y, Chatham L, et al. (2012b). Generation and characterization of novel cytochrome P450 Cyp2c gene cluster knockout and CYP2C9 humanized mouse lines. Mol Pharmacol 82: 1022-9.
53. Scheer N, Kapelyukh Y, McEwan J, et al. (2012c). Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. Mol Pharmacol 81:63-72.
54. Scheer N, Ross J, Kapelyukh Y, et al. (2010). In vivo responses of the human and murine pregnane X receptor to dexamethasone in mice. Drug Metab Dispos 38:1046-53.
55. Scheer N, Ross J, Rode A, et al. (2008). A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest 118:3228-39.
56. Scheer N, Wolf CR. (2013). Xenobiotic receptor humanized mice and their utility. Drug Metab Rev 45:110-21.
57. Shen HW, Wu C, Jiang XL, Yu AM. (2010). Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy- N,N-dimethyltryptamine metabolism and pharmacokinetics. Biochem Pharmacol 80:122-8.
58. Sugamori KS, Brenneman D, Grant DM. (2011). Liver-selective expression of human arylamine N-acetyltransferase NAT2 in transgenic mice. Drug Metab Dispos 39:882-90.
59. ter Heine R, Van Waterschoot RA, Keizer RJ, et al (2011). An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir. J Pharm Sci 100: 2508-15.
60. van de Steeg E, Stranecky V, Hartmannova H, et al. (2012). Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 122:519-28.
61. van de Steeg E, van der Kruijssen CM, Wagenaar E, et al. (2009). Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 37:277-81.
62. van de Steeg E, van Esch A, Wagenaar E, et al. (2013). Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin Cancer Res 19:821-32.
63. van de Steeg E, Wagenaar E, van der Kruijssen CM, et al. (2010). Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 120:2942-52.
64. van Herwaarden AE, Smit JW, Sparidans RW, et al. (2005). Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4. Drug Metab Dispos 33:892-5.
65. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, et al. (2007). Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117: 3583-92.
66. van Waterschoot RA, Rooswinkel RW, Sparidans RW, et al. (2009a). Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam. Drug Metab Dispos 37:2305-13.
67. van Waterschoot RA, Rooswinkel RW, Wagenaar E, et al. (2009b). Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB J 23: 224-31.
68. van Waterschoot RA, van Herwaarden AE, Lagas JS, et al. (2008). Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol Pharmacol 73:1029-36.
69. Vlaming ML, Mohrmann K, Wagenaar E, et al. (2006). Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther 318:319-27.
70. Wei Y, Wu H, Li L, et al. (2012). Generation and characterization of a CYP2A13/2B6/2F1-transgenic mouse model. Drug Metab Dispos 40: 1144-50.
71. Williams JA, Hyland R, Jones BC, et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32:1201-8.
72. Yang Q, Nagano T, Shah Y, et al. (2008). The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Toxicol Sci 101:132-9.
73. Yu AM, Fukamachi K, Krausz KW, et al. (2005). Potential role for human cytochrome P450 3A4 in estradiol homeostasis. Endocrinology 146:2911-19.
74. Yueh MF, Mellon PL, Tukey RH. (2011). Inhibition of human UGT2B7 gene expression in transgenic mice by the constitutive androstane receptor. Mol Pharmacol 79:1053-60.
75. Zhang QY, Gu J, Su T, et al. (2005). Generation and characterization of a transgenic mouse model with hepatic expression of human CYP2A6. Biochem Biophys Res Commun 338:318-24.
76. Zimniak P. (1993). Dubin-Johnson and Rotor syndromes: molecular basis and pathogenesis. Semin Liver Dis 13:248-60.